Decrease of junctional zone area in low protein placentas at E10.5, E17.5 and E18.5. by Paula N. Gonzalez (372538)

Figure S1 - Docosahexaenoic Acid Decreases Pro-Inflammatory Mediators in an <i>In Vitro</i> Murine Adipocyte Macrophage Co-Culture Model by Anna A. De Boer (510740)

N2142A mutation reduced viral replication and binding to cell by impairing receptor binding. by Xue Li (285380)

Subjects:

Source data for Fig 1. by Rahsan Erdem (11726357)

Source data for Fig 2. by Rahsan Erdem (11726357)

Source data for Fig 3. by Rahsan Erdem (11726357)

Demographics and baseline characteristics of the safety population. by Rahsan Erdem (11726357)

Grading of stool consistency and diarrhea severity. by Rahsan Erdem (11726357)

Secondary efficacy endpoints for the modified intent-to-treat population. by Rahsan Erdem (11726357)

Source data for S1 and S2 Figs. by Rahsan Erdem (11726357)

Consolidated Standards for Reporting of Trials flow diagram. by Rahsan Erdem (11726357)

Diarrheal disease severity by treatment group for the modified intent-to-treat population. by Rahsan Erdem (11726357)

iOWH032 inhibits cholera toxin-induced secretion in a mouse closed-loop model. by Rahsan Erdem (11726357)

Study drug–related treatment-emergent adverse events by system organ class and preferred term in the safety population. by Rahsan Erdem (11726357)

Diarrheal stool output rate overall and by blood type status in the modified intent-to-treat population. by Rahsan Erdem (11726357)

iOWH032 inhibits cholera toxin-induced fecal output in a cecectomized rat model. by Rahsan Erdem (11726357)

Reverse cumulative distribution plot for diarrheal stool output rate overall in the modified intent-to-treat population. by Rahsan Erdem (11726357)

Scatterplot of iOWH032 plasma concentrations versus diarrheal stool output rate. by Rahsan Erdem (11726357)

Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

“…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”